Lost Money on Humacyte, Inc. Join Class Action Suit Seeking Recovery -- Contact The ...
HUMA Stock | USD 4.10 0.02 0.49% |
About 63% of Humacyte's investor base is looking to short. The analysis of the overall investor sentiment regarding Humacyte suggests that many traders are alarmed. The current market sentiment, together with Humacyte's historical and current headlines, can help investors time the market. In addition, many technical investors use Humacyte stock news signals to limit their universe of possible portfolio assets.
Humacyte |
NEW YORK, Dec. 10, 2024 -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. . Shareholders who purcha
Read at gurufocus.com
Humacyte Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Humacyte can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Humacyte Fundamental Analysis
We analyze Humacyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Humacyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Humacyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Humacyte is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Humacyte Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Humacyte stock to make a market-neutral strategy. Peer analysis of Humacyte could also be used in its relative valuation, which is a method of valuing Humacyte by comparing valuation metrics with similar companies.
Peers
Humacyte Related Equities
LRMR | Larimar Therapeutics | 0.98 | ||||
SEER | Seer | 0.41 | ||||
MIRM | Mirum Pharmaceuticals | 0.38 | ||||
KALV | Kalvista Pharmaceuticals | 0.57 | ||||
KURA | Kura Oncology | 0.62 | ||||
VRDN | Viridian Therapeutics | 0.78 | ||||
MNOV | MediciNova | 1.38 | ||||
NRIX | Nurix Therapeutics | 1.41 | ||||
GPCR | Structure Therapeutics | 1.45 | ||||
CYTK | Cytokinetics | 3.16 | ||||
CRNX | Crinetics Pharmaceuticals | 3.52 | ||||
IMCR | Immunocore Holdings | 4.62 | ||||
QSI | QuantumSi | 4.97 | ||||
HCWB | HCW Biologics | 7.69 | ||||
LYRA | Lyra Therapeutics | 10.00 |
Complementary Tools for Humacyte Stock analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
CEOs Directory Screen CEOs from public companies around the world |